SCHEMBL561015

SCHEMBL561015

COc1ccc(Oc2cnc(N)c(-c3nc4ccc(C)cc4[nH]3)n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 8/20 0.52
CHEK2 O96017 3/20 0.46
TP53 P04637 4/20 0.46
NPC1 O15118 4/20 0.46
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
PKM P14618 3/20 0.46
HPGD P15428 3/20 0.46
MEN1 O00255 2/20 0.46
POLB P06746 2/20 0.46
KMT2A Q03164 2/20 0.46
LMNA P02545 1/20 0.46
ALOX5 P09917 1/20 0.45
EPHX2 P34913 1/20 0.45
RAB9A P51151 3/20 0.44
KDM4E B2RXH2 2/20 0.44
MAPT P10636 2/20 0.44
GAA P10253 1/20 0.44
HTT P42858 1/20 0.43
RUNX1 Q01196 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL560755 0.90 ATR (0.51) ATRCHEK2TP53NPC1ALDH1A1
SCHEMBL559946 0.90 ATR (0.51) ATRCHEK2TP53NPC1ALDH1A1
SCHEMBL560098 0.90 ATR (0.53) ATRCHEK2TP53NPC1ALDH1A1
SCHEMBL559824 0.87 ATR (0.54) ATRCHEK2
SCHEMBL10165965 0.87 ATR (0.52) ATRCHEK2TP53NPC1ALDH1A1
SCHEMBL561073 0.87 CHEK2 (0.54) ATRCHEK2
SCHEMBL560062 0.86 ATR (0.49) ATRCHEK2TP53NPC1ALDH1A1
SCHEMBL560707 0.84 ALDH1A1 (0.53) ATRCHEK2TP53NPC1ALDH1A1
SCHEMBL560431 0.84 ATR (0.49) ATRCHEK2TP53NPC1ALDH1A1
SCHEMBL560172 0.82 ATR (0.51) ATRTP53NPC1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
EP-2569289-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2013-03-20 EP disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
WO-2011143419-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 ATR 1/4885CHEK2 3/4885TP53 396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.